4.81
price up icon6.65%   0.30
after-market After Hours: 4.81
loading
Alumis Inc stock is traded at $4.81, with a volume of 442.04K. It is up +6.65% in the last 24 hours and up +18.77% over the past month. Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.51
Open:
$4.51
24h Volume:
442.04K
Relative Volume:
0.69
Market Cap:
$465.99M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1794
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+1.05%
1M Performance:
+18.77%
6M Performance:
+12.38%
1Y Performance:
-59.58%
1-Day Range:
Value
$4.51
$4.81
1-Week Range:
Value
$4.37
$4.83
52-Week Range:
Value
$2.7601
$13.00

Alumis Inc Stock (ALMS) Company Profile

Name
Name
Alumis Inc
Name
Phone
650-231-6625
Name
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
252
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ALMS's Discussions on Twitter

Compare ALMS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALMS
Alumis Inc
4.81 469.33M 0 -238.77M -216.62M -26.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
420.05 108.04B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
478.58 60.75B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.31 61.26B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
829.83 50.32B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
164.02 33.75B 398.11M -1.03B -868.57M -5.7032

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-25-25 Initiated Wells Fargo Overweight
Jun-10-25 Resumed Guggenheim Buy
Jan-30-25 Initiated Oppenheimer Outperform
Oct-31-24 Initiated Robert W. Baird Outperform
Oct-17-24 Initiated H.C. Wainwright Buy
Jul-23-24 Initiated Cantor Fitzgerald Overweight
Jul-23-24 Initiated Guggenheim Buy
Jul-23-24 Initiated Leerink Partners Outperform
Jul-23-24 Initiated Morgan Stanley Overweight
View All

Alumis Inc Stock (ALMS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alumis Inc Stock (ALMS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Tananbaum James B.
Director
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Labs, LLC
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Labs, LLC
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Capital Management VI
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Capital Management VI
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
AKKARAJU SRINIVAS
Director
May 05 '25
Buy
4.67
160,370
749,676
3,586,788
AKKARAJU SRINIVAS
Director
May 02 '25
Buy
4.55
159,920
727,636
3,426,418
Colowick Alan
Director
Apr 01 '25
Buy
6.97
16,104
112,309
16,104
Colowick Alan
Director
Apr 02 '25
Buy
7.49
2,300
17,235
18,404
Babler Martin
President, CEO and Chairman
Apr 01 '25
Buy
6.44
15,650
100,733
106,454
$37.26
price up icon 0.00%
$93.08
price up icon 1.97%
$29.03
price down icon 2.88%
$106.05
price up icon 0.37%
biotechnology ONC
$315.43
price up icon 1.49%
$164.02
price up icon 2.73%
Cap:     |  Volume (24h):